Wilson Sonsini Goodrich & Rosati's legacy closely traces the birth and evolution of Silicon Valley.
For six decades, Wilson Sonsini has represented the technology pioneers associated with virtually every milestone innovation.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Leading Matters
Client Highlights
Firm Advises Globalization Partners on $200 Million Investment from Vista Credit Partners
On January 24, 2022, Globalization Partners, the leading global employment platform that simplifies remote team building by making it fast and easy for companies to hire anyone, anywhere, within minutes, announced that it has received a $200 million investment from Vista Credit Partners, a subsidiary of Vista Equity Partners, and strategic credit and financing partner focused on the enterprise software, data, and technology markets. The investment values Globalization Partners at $4.2 billion. Wilson Sonsini Goodrich & Rosati advised Globalization Partners on the transaction.
Client Highlights
Wilson Sonsini Advises ONI on $75 Million Series B
On January 20, 2022, ONI, a biotechnology company democratizing the ability to observe single molecules in living cells with its desktop Nanoimager microscopy platform, announced the closing of a $75 million Series B funding round. The round was led by ARCH Venture Partners and Casdin Capital with participation from Section 32, ARTIS Ventures, Vertical Venture Partners, Axon Ventures, and private investors, including Paul Conley. Existing investors, including Oxford Science Enterprises, also participated in the round. Wilson Sonsini Goodrich & Rosati advised ONI on the transaction.
Client Highlights
Wilson Sonsini Advises Iterative Scopes on $150 Million Series B Funding
On January 19, 2022, Iterative Scopes, a pioneer in the development of precision-based gastrointestinal (GI) disease technologies and software, announced that it has raised $150 million in Series B financing to accelerate development of its core algorithmic innovations that are designed to transform gastroenterology care for patients. The round was co-led by Insight Partners and Clearlake Capital Group, L.P. (together with certain of its affiliates, “Clearlake”), as well as by returning investors Obvious Ventures, Johnson and Johnson Innovation-JJDC Inc., Eli Lilly, Breyer Capital, and other industry and financial leaders. Wilson Sonsini Goodrich & Rosati advised Iterative Scopes on the transaction.
Client Highlights
Wilson Sonsini Advises Codex DNA on Collaboration, License Agreement with Pfizer
On January 10, 2022, Codex DNA, a leader in the development of automated solutions for on-demand synthesis of genes and mRNA, announced a strategic collaboration and licensing agreement with Pfizer to access and further develop Codex DNA’s novel EDS technology for potential application by Pfizer for its mRNA-based vaccines and other biopharma products. Wilson Sonsini Goodrich & Rosati advised Codex DNA on the transaction.
The financial terms of the deal include an upfront payment from Pfizer to Codex DNA, along with success-based technical milestone payments that could be earned in the near term. Codex DNA is also eligible to receive additional milestone payments based on the achievement of specified development, regulatory, and commercialization goals associated with any products developed from the application of Codex DNA’s technology developed and licensed under the agreement. With this agreement, Pfizer gains early access to custom, state-of-the-art Codex DNA technology, including use of its proprietary short oligo ligation assembly (SOLA) EDS technology. SOLA EDS is a patent-pending, sustainable, scalable, and cost-effective research approach designed to significantly reduce timelines for constructing synthetic DNA, RNA, and protein, which could potentially lead to more efficient and effective research and development of mRNA-based vaccines, therapeutics, personalized medicines, and other biopharma products.
The financial terms of the deal include an upfront payment from Pfizer to Codex DNA, along with success-based technical milestone payments that could be earned in the near term. Codex DNA is also eligible to receive additional milestone payments based on the achievement of specified development, regulatory, and commercialization goals associated with any products developed from the application of Codex DNA’s technology developed and licensed under the agreement. With this agreement, Pfizer gains early access to custom, state-of-the-art Codex DNA technology, including use of its proprietary short oligo ligation assembly (SOLA) EDS technology. SOLA EDS is a patent-pending, sustainable, scalable, and cost-effective research approach designed to significantly reduce timelines for constructing synthetic DNA, RNA, and protein, which could potentially lead to more efficient and effective research and development of mRNA-based vaccines, therapeutics, personalized medicines, and other biopharma products.
Client Highlights
Wilson Sonsini Advises Verana Health on $150 Million Series E Funding
On January 14, 2022, Verana Health, a digital health company that delivers quality drug lifecycle and medical practice insights from an exclusive real-world data network, announced a $150 million Series E funding round led by Johnson & Johnson Innovation and Novo Growth, the growth-stage investment arm of Novo Holdings. Existing Verana Health investors GV (formerly Google Ventures), Casdin Capital, and Brook Byers also joined the round, as well as notable new investors, including the Merck Global Health Innovation Fund, THVC, and Breyer Capital. Verana Health plans to use the proceeds of the investment to advance its life sciences product and service strategy across the drug lifecycle, further enhance its value proposition to healthcare providers participating in its real-world data network, and expand its data footprint through medical society and strategic partnerships.
Client Highlights
Firm Advises Insilico Medicine on Drug Discovery Collaboration with Fosun Pharma
On January 11, 2022, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a leading innovation-driven international healthcare group in China, and Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery and development company, announced that they have entered into a collaboration agreement to advance the discovery and development of drugs targeting a number of different targets globally through the use of AI technology. Wilson Sonsini Goodrich & Rosati advised Insilico on the transaction.
The Life Sciences Report - January 2022
This latest issue features articles on Foresight Diagnostics co-founder and CEO Jake Chabon, recent pharmaceutical antitrust developments and expectations for 2022, life sciences venture financings in which clients participated across 2H 2020 and 1H 2021, and the firm’s newly launched Salt Lake City office. It also includes a discussion of the Genus v. FDA decision, the FDA’s regulatory framework for innovator drug products and public disclosures, and a summary of select recent life sciences client highlights.